These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16602148)

  • 1. Letrozole or tamoxifen in early breast cancer.
    Erban JK
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602148
    [No Abstract]   [Full Text] [Related]  

  • 2. Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
    Denes AE
    N Engl J Med; 2005 Nov; 353(21):2304-5; author reply 2304-5. PubMed ID: 16306534
    [No Abstract]   [Full Text] [Related]  

  • 3. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
    Forciniti S
    Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
    [No Abstract]   [Full Text] [Related]  

  • 4. Letrozole or tamoxifen in early breast cancer.
    Chlebowski RT
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602149
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
    Munster PN; Horton J
    Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
    [No Abstract]   [Full Text] [Related]  

  • 6. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 7. World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
    [No Abstract]   [Full Text] [Related]  

  • 8. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U
    MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
    [No Abstract]   [Full Text] [Related]  

  • 9. Extended adjuvant therapy for breast cancer--how much is enough?
    Prowell TM; Stearns V
    J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATAC trial update.
    de Castro G
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
    [No Abstract]   [Full Text] [Related]  

  • 12. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole or tamoxifen in early breast cancer.
    Buzdar AU; Baum M; Cuzick J
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
    [No Abstract]   [Full Text] [Related]  

  • 15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
    Crivellari D; Sun Z; Coates AS; Price KN; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens RJ; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Gladieff L; Rabaglio M; Smith IE; Chirgwin JH; Goldhirsch A
    J Clin Oncol; 2008 Apr; 26(12):1972-9. PubMed ID: 18332471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming recurrence risk: extended adjuvant endocrine therapy.
    Cianfrocca M
    Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract]   [Full Text] [Related]  

  • 20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.